Brokerages predict that Teligent Inc (NASDAQ:TLGT) will report ($0.02) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Teligent’s earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.03). The firm is scheduled to announce its next earnings report on Tuesday, November 12th.
On average, analysts expect that Teligent will report full-year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.18) to ($0.11). For the next year, analysts forecast that the company will post earnings of ($0.01) per share, with EPS estimates ranging from ($0.12) to $0.10. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Teligent.
Teligent (NASDAQ:TLGT) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $18.34 million during the quarter, compared to analysts’ expectations of $17.58 million. Teligent had a negative net margin of 46.67% and a negative return on equity of 102.17%.
Several equities analysts have recently weighed in on the company. ValuEngine lowered Teligent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Raymond James lowered Teligent from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 3rd. Finally, Zacks Investment Research lowered Teligent from a “hold” rating to a “sell” rating in a research note on Friday, October 4th.
Shares of NASDAQ TLGT traded up $0.02 during midday trading on Friday, hitting $0.75. The stock had a trading volume of 22,890 shares, compared to its average volume of 192,699. The company has a market capitalization of $42.54 million, a price-to-earnings ratio of -2.29 and a beta of 1.42. Teligent has a 1-year low of $0.42 and a 1-year high of $3.60. The company has a quick ratio of 0.86, a current ratio of 1.61 and a debt-to-equity ratio of 23.23. The company has a fifty day moving average price of $0.90 and a 200 day moving average price of $0.81.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Teligent by 496.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 59,887 shares of the company’s stock valued at $37,000 after purchasing an additional 49,852 shares in the last quarter. TENOR CAPITAL MANAGEMENT Co. L.P. acquired a new position in shares of Teligent in the 2nd quarter valued at about $44,000. Morgan Stanley lifted its position in Teligent by 247.0% during the 2nd quarter. Morgan Stanley now owns 72,655 shares of the company’s stock worth $45,000 after acquiring an additional 51,718 shares in the last quarter. Jane Street Group LLC acquired a new position in Teligent during the 2nd quarter worth approximately $46,000. Finally, SG Americas Securities LLC acquired a new position in Teligent during the 2nd quarter worth approximately $47,000. 55.31% of the stock is currently owned by institutional investors and hedge funds.
Teligent Company Profile
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
See Also: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.